Efficacy of Topical TolaSure on Acute Induced Wounds in Healthy Participants
Launched by BIOMENDICS, LLC · Sep 11, 2019
Trial Information
Current as of June 13, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Healthy Males and Females \> 18 years of age
- • Health history review
- • Physical exam
- • Blood and urine clinical chemistries
- • Negative pregnancy test
- Exclusion Criteria:
- • Acute or chronic skin disorders (e.g. psoriasis);
- • Acne or dermatitis at the test site;
- • Prone to keloids or hypertrophic scarring;
- • Topical or systemic antibiotics within 4 weeks of study enrollment;
- • Subjects with known severe mental illness which, in the investigator's opinion, may prevent informed consent or interfere with the subject's ability to comply with study protocol procedures;
- • Diagnosed with Diabetes Type I/II or glucose results indicative of prediabetic condition;
- • Morbidly obese with a Body Mass Index (BMI) ≥ 40;
- • Surgery within the previous 3 months (except for minor cosmetic or dental procedures)
- • History of severe vitamin or mineral deficiency;
- • History of drug or alcohol abuse (as defined by the Investigator);
- • Smoking/Vaping;
- • HIV/AIDS;
- • Consistently taking steroids and/or non-steroidal anti-inflammatory drugs. Subjects may use NSAIDs on an as needed basis with no more than 7 days of consecutive use;
- • Cancer diagnosis in the last 5 years;
- • Currently receiving chemotherapy or radiation;
- • Women who are pregnant, nursing, or planning a pregnancy;
- • Hyper- or hypo-pigmentation, or tattoos in the area where they will place the test fields;
- • Symptoms of a clinically significant illness in the four weeks before treatment application that may influence the outcome of the study;
- • Treatment with any investigational agent within one month before treatment application for this trial;
- • Unwilling or unable to comply with the requirements of this protocol, including the presence of any condition (physical, mental, or social) that is likely to affect the subject's return for follow-up visits on schedule;
- • Other unspecified reasons that, in the opinion of the Investigator, make the subject unsuitable for enrollment.
About Biomendics, Llc
Biomendics, LLC is a forward-thinking clinical trial sponsor dedicated to advancing innovative therapeutic solutions in the healthcare sector. With a focus on enhancing patient outcomes through rigorous research and development, the company partners with healthcare professionals and institutions to conduct high-quality clinical trials. Biomendics emphasizes a patient-centric approach, ensuring that safety and efficacy are at the forefront of its studies. Committed to scientific integrity and operational excellence, Biomendics aims to contribute significantly to the development of novel treatments that address unmet medical needs.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Miami, Florida, United States
College Station, Texas, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials